Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00061655" target="_blank" >RIV/00216224:14110/12:00061655 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1111/j.1478-3231.2012.02819.x" target="_blank" >http://dx.doi.org/10.1111/j.1478-3231.2012.02819.x</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/j.1478-3231.2012.02819.x" target="_blank" >10.1111/j.1478-3231.2012.02819.x</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
Popis výsledku v původním jazyce
Background & Aims Peginterferon plus ribavirin has been the standard of care for chronic hepatitis C for a decade and an essential component of combination regimens for this disease. This large multinational open-label study aimed to better define the incidence of serious adverse events (SAEs) and non-serious adverse events of special interest in patients receiving peginterferon alfa-2a/ribavirin. Methods Patients were assigned at the investigator's discretion to 24- or 48-week treatment with peginterferon alfa-2a 180 mmg/week and ribavirin 800 mg/day or 1000/1200 mg/day. All AEs, defined as SAEs and non-SAEs of special interest, were recorded during treatment and for 12 weeks thereafter. Non-SAEs of special interest included those leading to dosereduction/discontinuation, neutropenia, thrombocytopenia, anaemia, ALT elevations leading to dose modification and unknown/unexpected AEs. Results Of 1675 and 7178 patients assigned to 24 and 48 weeks of treatment, respectively, 87.6 and
Název v anglickém jazyce
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
Popis výsledku anglicky
Background & Aims Peginterferon plus ribavirin has been the standard of care for chronic hepatitis C for a decade and an essential component of combination regimens for this disease. This large multinational open-label study aimed to better define the incidence of serious adverse events (SAEs) and non-serious adverse events of special interest in patients receiving peginterferon alfa-2a/ribavirin. Methods Patients were assigned at the investigator's discretion to 24- or 48-week treatment with peginterferon alfa-2a 180 mmg/week and ribavirin 800 mg/day or 1000/1200 mg/day. All AEs, defined as SAEs and non-SAEs of special interest, were recorded during treatment and for 12 weeks thereafter. Non-SAEs of special interest included those leading to dosereduction/discontinuation, neutropenia, thrombocytopenia, anaemia, ALT elevations leading to dose modification and unknown/unexpected AEs. Results Of 1675 and 7178 patients assigned to 24 and 48 weeks of treatment, respectively, 87.6 and
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FN - Epidemiologie, infekční nemoci a klinická imunologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2012
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Liver International
ISSN
1478-3223
e-ISSN
—
Svazek periodika
32
Číslo periodika v rámci svazku
8
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
8
Strana od-do
1270-1277
Kód UT WoS článku
000307722000011
EID výsledku v databázi Scopus
—